INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2019. The put-call ratio across all filers is 2.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,467,000 | -18.5% | 31,532 | 0.0% | 0.01% | -12.5% |
| Q2 2022 | $1,800,000 | -94.8% | 31,532 | -94.5% | 0.02% | -93.7% |
| Q1 2022 | $34,806,000 | +15.7% | 568,811 | -1.1% | 0.25% | +18.1% |
| Q4 2021 | $30,094,000 | +38.0% | 574,978 | -1.7% | 0.22% | +30.3% |
| Q3 2021 | $21,812,000 | +173.2% | 585,074 | +199.2% | 0.16% | +179.7% |
| Q2 2021 | $7,983,000 | +267.2% | 195,560 | +198.0% | 0.06% | +293.3% |
| Q4 2019 | $2,174,000 | +405.6% | 65,619 | +14.0% | 0.02% | +400.0% |
| Q3 2019 | $430,000 | -53.3% | 57,557 | -18.8% | 0.00% | -50.0% |
| Q2 2019 | $920,000 | +77.6% | 70,869 | +66.9% | 0.01% | +50.0% |
| Q1 2019 | $518,000 | – | 42,460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
| EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
| Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
| Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
| SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
| GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
| BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
| Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
| Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
| Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |